600 results on '"Eisen, Tim"'
Search Results
2. Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma
3. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
4. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
5. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting
6. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
7. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
8. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
9. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol
10. Clinical features and management
11. The nature and development of cancer: Cancer mutations and their implications
12. Malignant diseases of the urinary tract
13. Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
14. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
15. Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma
16. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
17. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK
18. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
19. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting
20. The CHRNA5–A3–B4 Gene Cluster and Smoking: From Discovery to Therapeutics
21. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
22. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
23. First-Generation Tyrosine Kinase Inhibitors: Clinical Results
24. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort
25. A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma
26. Data from The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
27. Supplementary Figures 1 - 2, Tables 1 - 3 from The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
28. Data from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
29. supplementary data from A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma
30. Supplementary Figure 1 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
31. Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
32. Supplementary Figure 2 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
33. Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
34. Supplementary Tables 1-7 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
35. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project
36. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
37. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer
38. Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma
39. Tumour Necrosis Factor – Misnomer and Therapeutic Target
40. Treatment of metastatic renal cancer
41. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
42. Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment
43. Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study
44. Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future
45. Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials
46. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
47. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
48. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
49. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points
50. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.